Form 4: NeuroBo Pharmaceuticals Director Receives Stock Grant and Reports Beneficial Ownership

Director Jason L. Groves receives a grant of restricted stock units and reports changes in beneficial ownership of NeuroBo Pharmaceuticals stock.

Summary

• On June 7, 2024, Jason L. Groves, a director of NeuroBo Pharmaceuticals, received a grant of 5,051 restricted stock units (RSUs) under the company's 2022 Equity Incentive Plan.
• These RSUs will vest on the earlier of June 7, 2025, or the day before the company's 2025 Annual Meeting of Stockholders, contingent upon Groves' continued service.
• Groves has elected to defer receipt of the shares upon vesting until a Change in Control or within 60 days of his retirement, separation from service, or death.
• The total number of securities beneficially owned by Groves is 17,552, adjusted to reflect a 1-for-8 reverse stock split completed on December 20, 2023.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing related to stock grants. It's neutral in tone and doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Positives

• The grant of RSUs aligns the director's interests with the long-term success of the company.
• The deferral of share receipt may indicate a belief in the company's future prospects.

Future Outlook

The vesting of the RSUs is contingent upon the director's continued service and may be affected by a Change in Control or separation from service.

Industry Context

This filing is a routine disclosure of stock grants to company directors, which is a common practice in publicly traded companies to incentivize and retain key personnel.

Stakeholder Impact

• The stock grant could potentially dilute existing shareholders if the shares are eventually issued.

Key Dates